A new technology is designed to be a “wearable” device for neurons, wrapping around individual nerve fibers with a goal of achieving new ways to study and treat neurological diseases like multiple sclerosis (MS). Still in early testing stages and needing further refinement, the technology was developed by scientists at…
Read more
As a native Floridian, I’ve been through my fair share of hurricanes. Because they’re so familiar, I’m probably a bit too indifferent to them. But in many ways, hurricanes parallel my life with relapsing-remitting multiple sclerosis (RRMS); each involves preparation, weathering of the storm, and adjusting to the aftermath.
The European Commission (EC) fined Teva Pharmaceuticals €462.6 million — more that $502 million — after an investigation it launched found the company illegally tried to stop competitor versions of Copaxone (glatiramer acetate injection), its blockbuster drug for multiple sclerosis (MS), from entering markets. Several patents…
Being diagnosed with relapsing-remitting multiple sclerosis doesn’t necessarily mean that other health complications or conditions won’t arise. According to an article published in the journal Multiple Sclerosis and Related Disorders, multiple sclerosis (MS) patients have significantly higher rates of comorbidity and morbidity than people who don’t have…
A first group of healthy adults has been dosed in a Phase 1 safety and tolerability trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis (MS), regardless of disease type. These initial volunteers will serve as the trial’s sentinels, an occasional study feature allowing for a…
Get regular updates to your inbox.
